SAL0132 / Shenzhen Salubris - LARVOL DELTA

A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications (clinicaltrials.gov) - P2 | N=560 | Not yet recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P2 trial • Cardiovascular • Hypertension

A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension (clinicaltrials.gov) - P2 | N=319 | Active, not recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P2 trial • Cardiovascular • Hypertension

A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics. (PubMed, Mol Ther Nucleic Acids) - "This platform integrates preclinical and clinical data from all seven FDA-approved GalNAc-siRNA drugs-fitusiran, givosiran, inclisiran, lumasiran, vutrisiran, nedosiran, and plozasiran-spanning multiple species (mouse, rat, monkey, and human). The platform successfully predicted the PK and simulated the PD profiles of SAL0132 in humans, which demonstrated model-informed strategies to support efficient drug development of this modality. In conclusion, this platform enables users to predict GalNAc-siRNA PK/PD profiles across species by inputting specific model parameters, providing a powerful resource to guide the development of next-generation GalNAc-siRNA therapeutics."

Journal

SUSTAINED REDUCTIONS IN ANGIOTENSINOGEN AND BLOOD PRESSURE WITH AN RNA INTERFERENCE THERAPEUTIC: INTERIM RESULTS FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF GW906 IN CHINA (ACC 2026) - "A single dose of GW906 produced profound and sustained reductions in serum AGT and BP without hypotension or serious adverse events."

First-in-human • P1 data • Cardiovascular • Hypertension • Hypotension